Performance of a new fluorescence-labeled MMP inhibitor to image tumor MMP activity in vivo in comparison to an MMP-activatable probe

Contrast Media and Molecular Imaging

Volumn 8, Issue 1, 2013, Pages 1-11

  Waschkau, Bianca ^a   Faust, Andreas ^b   Schäfers, Michael ^b   Bremer, Christoph ^a,b  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Activatable probes; Cancer; FRI; MMP 2; MMP 9; MMP inhibitor; NIRF imaging

Indexed keywords

COLLAGENASE; CY5.5 AF 489; CYSTEINE; GELATINASE; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MESSENGER RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG DISTRIBUTION; DRUG POTENCY; ENZYME ACTIVITY; FLUORESCENCE; FLUORESCENCE IMAGING; FLUORESCENCE REFLECTANCE IMAGING; IMMUNOHISTOCHEMISTRY; IN SITU ZYMOGRAPHY; IN VIVO STUDY; MOLECULAR PROBE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; ZYMOGRAPHY;

ANIMALS; CARBOCYANINES; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASE INHIBITORS; MICE; MICE, NUDE; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; NEOPLASMS; OPTICAL IMAGING; RNA, MESSENGER; TRANSPLANTATION, HETEROLOGOUS;

EID: 84868155168     PISSN: 15554309     EISSN: 15554317     Source Type: Journal    
DOI: 10.1002/cmmi.1486     Document Type: Article

References (44)

1. Hijova E. Matrix metalloproteinases: their biological functions and clinical implications. Bratisl Lek Listy 2005; 106(3): 127-132.
2. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circul Res 2002; 90(3): 251-262.
3. Squire IB, Evans J, Ng LL, Loftus IM, Thompson MM. Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction. J Card Fail 2004; 10(4): 328-333.
4. Giannelli G, Erriquez R, Iannone F, Marinosci F, Lapadula G, Antonaci S. MMP-2, MMP-9, TIMP-1 and TIMP-2 levels in patients with rheumatoid arthritis and psoriatic arthritis. Clin Exp Rheumatol 2004; 22(3): 335-338.
5. Avolio C, Ruggieri M, Giuliani F, Liuzzi GM, Leante R, Riccio P, Livrea P, Trojano M. Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J Neuroimmunol 2003; 136(1-2): 46-53.
6. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev 2002; 2(3): 161-174.
7. Stetler-Stevenson WG. Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev 1990; 9(4): 289-303.
8. Karakiulakis G, Papanikolaou C, Jankovic SM, Aletras A, Papakonstantinou E, Vretou E, Mirtsou-Fidani V. Increased type IV collagen-degrading activity in metastases originating from primary tumors of the human colon. Invasion Metastasis 1997; 17(3): 158-168.
9. Duffy MJ, McCarthy K. Matrix metalloproteinases in cancer: prognostic markers and targets for therapy (review). Int J Oncol 1998; 12(6): 1343-1348.
10. Hrabec E, Strek M, Nowak D, Greger J, Suwalski M, Hrabec Z. Activity of type IV collagenases (MMP-2 and MMP-9) in primary pulmonary carcinomas: a quantitative analysis. J Cancer Res Clin Oncol 2002; 128(4): 197-204.
11. Zeng ZS, Huang Y, Cohen AM, Guillem JG. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol 1996; 14(12): 3133-3140.
12. Scherer RL, McIntyre JO, Matrisian LM. Imaging matrix metalloproteinases in cancer. Cancer Metastasis Rev 2008; 27(4): 679-690.
13. Joshi BP, Wang TD. Exogenous molecular probes for targeted imaging in cancer: focus on multi-modal imaging. Cancers 2010; 2(2): 1251-1287.
14. Weissleder R, Tung CH, Mahmood U, Bogdanov A, Jr. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol 1999; 17(4): 375-378.
15. Lee S, Park K, Lee SY, Ryu JH, Park JW, Ahn HJ, Kwon IC, Youn IC, Kim K, Choi K. Dark quenched matrix metalloproteinase fluorogenic probe for imaging osteoarthritis development in vivo. Bioconjugate Chem 2008; 19(9): 1743-1747.
16. Zhu L, Xie J, Swierczewska M, Zhang F, Quan Q, Ma Y, Fang X, Kim K, Lee S, Chen X. Real-time video imaging of protease expression in vivo. Theranostics 2011; 1: 18-27.
17. Whittaker M, Floyd CD, Brown P, Gearing AJ. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev 1999; 99(9): 2735-2776.
18. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science (NY) 2002; 295(5564): 2387-2392.
19. Fisher JF, Mobashery S. Recent advances in MMP inhibitor design. Cancer Metastasis Rev 2006; 25(1): 115-136.
20. Schäfers M, Riemann B, Kopka K, Breyholz HJ, Wagner S, Schäfers KP, Law MP, Schober O, Levkau B. Scintigraphic imaging of matrix metalloproteinase activity in the arterial wall in vivo. Circulation 2004; 109(21): 2554-2559.
21. Su H, Spinale FG, Dobrucki LW, Song J, Hua J, Sweterlitsch S, Dione DP, Cavaliere P, Chow C, Bourke BN, Hu XY, Azure M, Yalamanchili P, Liu R, Cheesman EH, Robinson S, Edwards DS, Sinusas AJ. Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling. Circulation 2005; 112(20): 3157-3167.
22. Zhang J, Nie L, Razavian M, Ahmed M, Dobrucki LW, Asadi A, Edwards DS, Azure M, Sinusas AJ, Sadeghi MM. Molecular imaging of activated matrix metalloproteinases in vascular remodeling. Circulation 2008; 118(19): 1953-1960.
23. Furumoto S, Takashima K, Kubota K, Ido T, Iwata R, Fukuda H. Tumor detection using 18F-labeled matrix metalloproteinase-2 inhibitor. Nucl Med Biol 2003; 30(2): 119-125.
24. Zheng QH, Fei X, Liu X, Wang JQ, Stone KL, Martinez TD, Gay DJ, Baity WL, Miller KD, Sledge GW, Hutchins GD. Comparative studies of potential cancer biomarkers carbon-11 labeled MMP inhibitors (S)-2-(4'-[11C]methoxybiphenyl-4-sulfonylamino)-3-methylbutyric acid and N-hydroxy-(R)-2-[[(4'-[11C]methoxyphenyl)sulfonyl]benzylamino]-3-methylbutanamide. Nucl Med Biol 2004; 31(1): 77-85.
25. Wagner S, Breyholz HJ, Law MP, Faust A, Höltke C, Schroer S, Haufe G, Levkau B, Schober O, Schäfers M, Kopka K. Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET. J Med Chem 2007; 50(23): 5752-5764.
26. Faust A, Waschkau B, Waldeck J, Höltke C, Breyholz HJ, Wagner S, Kopka K, Schober O, Heindel W, Schäfers M, Bremer C. Synthesis and evaluation of a novel hydroxamate based fluorescent photoprobe for imaging of matrix metalloproteinases. Bioconjug Chem 2009; 20(5): 904-912.
27. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17: 463-516.
28. Köhrmann A, Kammerer U, Kapp M, Dietl J, Anacker J. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: new findings and review of the literature. BMC Cancer 2009; 9: 188.
29. Giambernardi TA, Grant GM, Taylor GP, Hay RJ, Maher VM, McCormick JJ, Klebe RJ. Overview of matrix metalloproteinase expression in cultured human cells. Matrix Biol 1998; 16(8): 483-496.
30. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94(6): 2493-2503.
31. Sukhova GK, Schonbeck U, Rabkin E, Schoen FJ, Poole AR, Billinghurst RC, Libby P. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 1999; 99(19): 2503-2509.
32. Herman MP, Sukhova GK, Libby P, Gerdes N, Tang N, Horton DB, Kilbride M, Breitbart RE, Chun M, Schonbeck U. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation 2001; 104(16): 1899-1904.
33. Tan RJ, Fattman CL, Niehouse LM, Tobolewski JM, Hanford LE, Li Q, Monzon FA, Parks WC, Oury TD. Matrix metalloproteinases promote inflammation and fibrosis in asbestos-induced lung injury in mice. Am J Respir Cell Mol Biol 2006; 35(3): 289-297.
34. Roomi MW, Monterrey JC, Kalinovsky T, Rath M, Niedzwiecki A. Inhibition of invasion and MMPs by a nutrient mixture in human cancer cell lines: a correlation study. Exp Oncol 2010; 32(4): 243-248.
35. Snoek-van Beurden PA, Von den Hoff JW. Zymographic techniques for the analysis of matrix metalloproteinases and their inhibitors. Biotechniques 2005; 38(1): 73-83.
36. Rundhaug JE. Matrix metalloproteinases, angiogenesis, and cancer: commentary re: A. C. Lockhart et al., Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clin Cancer Res 2003; 9(2): 551-554.
37. Klohs J, Baeva N, Steinbrink J, Bourayou R, Boettcher C, Royl G, Megow D, Dirnagl U, Priller J, Wunder A. In vivo near-infrared fluorescence imaging of matrix metalloproteinase activity after cerebral ischemia. J Cereb Blood Flow Metab 2009; 29(7): 1284-1292.
38. Zhang Q, Yang M, Shen J, Gerhold LM, Hoffman RM, Xing HR. The role of the intravascular microenvironment in spontaneous metastasis development. Int J Cancer 2010; 126(11): 2534-2541.
39. Clapper ML, Hensley HH, Chang WC, Devarajan K, Nguyen MT, Cooper HS. Detection of colorectal adenomas using a bioactivatable probe specific for matrix metalloproteinase activity. Neoplasia (NY) 2011; 13(8): 685-691.
40. Pham W, Choi Y, Weissleder R, Tung CH. Developing a peptide-based near-infrared molecular probe for protease sensing. Bioconjug Chem 2004; 15(6): 1403-1407.
41. Eisenblätter M, Höltke C, Persigehl T, Bremer C. Optical techniques for the molecular imaging of angiogenesis. Eur J Nucl Med Mol Imag 2010; 37 Suppl 1: S127-137.
42. Perkin Elmer Inc. In Vivo Technology. Available from: http://www.perkinelmer.com/search/Search.aspx?Ntt=MMPSEnse&N=114.
43. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29(9): e45.
44. Galis ZS, Sukhova GK, Libby P. Microscopic localization of active proteases by in situ zymography: detection of matrix metalloproteinase activity in vascular tissue. FASEB J 1995; 9(10): 974-980.